Withaferin A Suppresses Liver Tumor Growth in a Nude Mouse Model by Downregulation of Cell Signaling Pathway Leading to Invasion and Angiogenesis
Abstract
Purpose: To investigate the effect of withaferin A on tumor growth and metastasis in liver in a nude mouse model.
Methods: Withaferin A was injected through a portal vein to the orthotopic liver tumor in a nude mice model. Xenogen in vivo imaging system was used to monitor tumor growth and metastasis. The effect of withaferin A on tumor volume, invasive growth pattern, expression of Pyk2, upregulation of BAX/P53, apoptotic signaling and ROCK/IP10/VEGF pathway along with cytoskeletal protein actin projection formation was studied. Tumor/non-tumor margin was examined under electron microscopy. In addition, the direct effect of withaferin A on liver cancer cells and endothelial cells was further investigated.
Results: A significant inhibition of tumor growth and lower incidence of lung metastasis was observed after withaferin A treatment. Withaferin A treatment led to a decrease in the incidence of intrahepatic metastasis from 90 (9 of 10) to 10 % (1 of 10, p = 0.041). There was decrease in macrophage infiltration in the liver tumors and vessels. Western blot analysis revealed inhibition of expression of Pyk2, ROCK1 protein and VEGF. Electron microscopy showed tumor vascular endothelial cell damage and significant necrosis of tumor tissues. It also suppressed formation of cytoskeletal protein actin projection involved in cell migration.
Conclusion: Withaferin A inhibits liver tumor invasion and angiogenesis by downregulation of cell signalling pathway leading to invasion and angiogenesis. Therefore, withaferin A is a promising candidate for the treatment of liver tumor invasion and angiogenesis.
Keywords: Withaferin A, Macrophage, Lung metastasis, Angiogenesis, Vascular endothelial growth factor, Rho kinase, Withania somnifera
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.